Download in electronic PDF format for $75

Abstract:  COVID-19 (coronavirus disease 2019), which is caused by the positive-stranded ribonucleic acid virus SARS-CoV-2 (acute respiratory syndrome coronavirus 2), is an extremely contagious airborne illness of pandemic proportions. In the modern era, few diseases other than COVID-19 have produced such severe, prolific, and protean short-term adverse effects and long-term sequelae. In addition, few other pandemics have exhibited a trajectory of morbidity and mortality so affected by social, economic, and political factors as well as individual personal perceptions and beliefs. Vaccines for the prevention of SARS-CoV-2 infection and treatments for COVID-19 mitigate associated morbidity and mortality, but an increasing array of variants presents challenges to therapeutic effectiveness. As a result, afflicted patients often require customized treatments that address the severity of their infection, the manifestations of disease they exhibit, and their individual pharmacogenomic profile. In such cases, a compounded preparation may offer needed support for recovery. This article, which is the first in a series on compounding for COVID-19 and long COVID (i.e., the long- term sequelae of SARS-CoV-2 infection), provides information about pertinent viral terminology and a brief overview of SARS-CoV-2 mutations and variants of note. Two formulations for customized compounds that may prove effective in treating the acute and/or long-term effects of COVID-19 when commercial therapies have failed are also provided.

Related Keywords: Mike Riepl, RPh, COVID-19, long COVID, coronavirus disease 2019, SARS-CoV-2 virus, acute respiratory syndrome coronavirus 2, pandemic, genetic variants, mutations, mutants, terminology, inflammation, proinflammatory cytokines, inflammatory response, lungs, airway, immune cell recruitment, complement cascade activation, formulations, D614G, naltrexone hydrochloride, N501Y, E484K, alpha variant, beta variant, gamma variant, delta variant, omicron variant

Related Categories: FORMULATIONS, INFECTIOUS DISEASE

Printer-Friendly Version